Singapore is making remarkable progress in the realm of cell and gene therapy (CGT), as evidenced by the inauguration of a state-of-the-art 2,000 sq m cell therapy facility. This establishment is a testament to the nation’s commitment to meeting the escalating demand for CGT, ensuring that patients receive these groundbreaking treatments promptly. This move is also timely as Singapore is now regarded as an aged society as 20% of its population of 6.5 million is now above the age of 65 years. This figure will rise to 25% by year 2030.
Facility Insights and Broader Implications:
- Infrastructure and Accessibility: Nestled under the Advanced Cell Therapy and Research Institute, Singapore (Actris) which was formed as a national agency in 2020, the facility boasts 14 clean suites that meet good manufacturing practice standards, four translational laboratories, and a quality control laboratory. This infrastructure is open to hospitals, research institutions, and budding biotech ventures, aiding their research in cell selection and genetic modification. This facility should be available for their use in 2024.
- Precision Medicine and Task Force: A specialized task force, led by the Ministry of Health (MOH) and chaired by Kenneth Mak, the director-general of health, has been established. Comprising clinicians, researchers, and health economists, this team is set to foster the rapidly growing domain of precision medicine.
- Economic and Ethical Aspects: While cell therapies, a subset of precision medicine, are revolutionary, they can be expensive. However, the sheer magnitude of the new facility might lead to a reduction in treatment costs. Minister for Health, Ong Ye Kung, has emphasized the importance of a sustainable financing model and highlighted the ethical challenges posed by gene and cell modifications.
- Strategic Positioning: The facility’s unveiling took place at the National Cancer Centre Singapore (NCCS) during the inaugural Singapore Cell and Gene Therapy Conference. Its strategic location within NCCS’s new 24-story building on the Singapore General Hospital (SGH) campus further accentuates its significance.
- Regional Impact: Actris chairman, Chee Yam Cheng, envisions the facility as a transformative force in Singapore’s cell therapy ecosystem. With the ability to produce top-tier cell therapies domestically, patients can access life-saving treatments faster. This initiative is poised to establish Singapore as a leader in the CGT sector in Asia, potentially inspiring neighboring nations to delve into this domain.
CytoMed Therapeutics: Pioneering Affordable Cellular Therapies in the region
Complementing Singapore’s strides in CGT is CytoMed Therapeutics (NASDAQ: GDTC). Originating from Singapore’s renowned Agency for Science, Technology and Research (A*Star) in 2018, CytoMed is revolutionizing cellular immunotherapy through their patented cells. Their mission is clear: to engineer cost-effective and potent cellular cancer therapies.
- Innovative Allogeneic off-the-shelf Cell Therapies: CytoMed is translating its patented and patent-pending technologies into gamma delta (γδ) T cells as well as immune cells derived from induced pluripotent stem cells. These therapies cater to a diverse range of cancers without the use of viral vectors and ease of manufacturing. Noteworthy technologies include the iPSC-γδ NKT Cell Technology and the NKG2DL CAR-γδ T Cell Technology, both of which amplify the body’s innate defense mechanisms against cancer.
- Affordability and Potential Efficacy: In a world where cellular therapies often come with hefty price tags, CytoMed’s approach stands out. Their focus on “allogeneic off-the-shelf” solutions and the utilization of iPSCs aims to democratize access to these treatments. Their broad-spectrum solutions, coupled with their foundation in scientific research, ensure that affordability doesn’t compromise efficacy.
In conclusion, Singapore’s investment in cell and gene therapies, combined with the innovative solutions offered by CytoMed Therapeutics, heralds a new era in medical science. Together, they can potentially transform cellular medicine and healthcare in Singapore and also position the nation as a hub of innovation in the Asian medical landscape.
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated one thousand seven hundred dollars cash for the creation and dissemination of this content by the company.
This material does not represent a solicitation to buy or sell any securities. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/